BIOMIC V3 reads and interprets several yeast antibiotic susceptibility and identification tests including:

• Sensititre YeastOne (TREK) YO-2V and YO-9
• API 20C, rapid ID 32 C (bioMerieux)
• RapID Yeast Plus (Remel)
• Etests (all antifungal strips)
• Antifungal disk diffusion testing

Antimicrobial Surveillance and Yeast Disk Test References

2009. M. A. Pfaller,  D. J. Diekema, D. L. Gibbs, V. A. Newell, H. Bijie, D. Dzierzanowska, N. N. Klimko, V. Letscher-Bru, M. Lisalova, K. Muehlethaler, C. Rennison, M. Zaidi and the Global Antifungal Surveillance Group.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. Journal of Clinical Microbiology 47(1) 117-123. View Abstract

2008. M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, E. Nagy, S. Dobiasova, M. Rinaldi, R. Barton, A. Veselov and the Global Antifungal Surveillance Group. Candida krusei, a Multidrug Resistant Opportunistic Fungal Pathogen: Geographical and Temporal Trends from the ARTEMIS DISK Global Antifungal Surveillance Program, 2001-2005. Journal of Clinical Microbiology 46(2) 515-521. View Abstract

2008. M.A. Pfaller, D.J. Diekema, D.L. Gibbs, V.A. Newell, K.P. Ng, A. Colombo, J. Finquelievich, R. Barnes, J. Wadula, and the Global Antifungal Surveillance Group. Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis: A Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology 46 (3) 842-849. View Abstract

2007. A. Espinel-Ingroff, B. Arthington-Skaggs, N. Iqbal, D. Ellis, M.A. Pfaller, S. Messer, M. Rinaldi, A. Fothergill, D. L. Gibbs, A. Wang. A Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin-B and Caspofungin. Journal of Clinical Microbiology 45(6), 1811-1820. View Abstract

2007. M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, J. F. Meis, I. M. Gould, W. Fu, A. L. Colombo, E. Rodriguez-Noriega, and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997-2005: An 8.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by CLSI Standardized Disk Diffusion Testing. Journal of Clinical Microbiology. 45(6), 1735-1745. View Abstract

2006. M. Pfaller, D. Diekema, A. Colombo, C. Kibbler, K. P. Ng, D. Gibbs, V. Newell and the Global Antifungal Surveillance Group. Candida rugosa, an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS Disk Antifungal Surveillance Program. Journal of Clinical Microbiology. 44, 3578-3582.

2006. M. Pfaller, D. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S. Chang, D. Gibbs, V. Newell, and the Global Antifungal Surveillance Group. Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS Disk Antifungal Surveillance Program. Journal of Clinical Microbiology 44, 3551-3556.

2006. Pfaller, M.& D. Diekema, D.Sheehan et al. Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. Clinical Microbiology Review. 19(2), 435-447. View Abstract

2006. M. Pfaller, D. Diekema, et al. Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints. Journal of Clinical Microbiology, 44(3), 819-826. View Abstract

2005. M. Pfaller, D. Diekema, M. Rinaldi, R. Barnes, B. Hu, A. Veselov, N. Tiraboschi, E. Nagy, D. Gibbs. Results for the ARTEMIS Disk Global Antifungal Surveillance Study: a 6.5-year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standard Disk Diffusion Testing. Journal of Clinical Microbiology. 43(2) 5848-5859. View Abstract

2005. D. Sheehan and D. Gibbs. In Vitro Activity of Voriconazole and Fluconazole Against Candida Species; a Report from the ARTEMIS Global Surveillance Program. Abstract, European Congress of Clinical Microbiology and Infectious Disease (ECCMID).

2005. D. Gibbs and D. Sheehan. In Vitro Activity of Voriconazole and Fluconazole Versus > 8000 Candida glabrata Isolates. Abstract, European Congress of Clinical Microbiology and Infectious Disease ECCMID.

2004. Clinical and Laboratory Standards Institute. Method for Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline M44-A. CLSI Wayne, PA. www.clsi.org

2003. K. C. Hazen, E. J. Baron, A. Colombo, C. Girmenia, A. Sanchez-Sousa, A. del Palacio, C. de Bedout, D. L. Gibbs, and the Global Antifungal Surveillance Group. Comparison of the Susceptibilities of Candida spp to Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk Diffusion. Journal of Clinical Microbiology, 41(12) 5623-5632.

2003. M. Pfaller et. al. Evaluation of the Etest and Disk Diffusion Methods for Determining Susceptibilities of 235 Bloodstream Isolates of Candida glabrata to Fluconazole and Voriconazole. Journal of Clinical Microbiology 41(5), 1875-1880.

2003. M. Pfaller et. al. Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001. Journal of Clinical Microbiology 41(4), 1440-1446.

2003. M. A. Pfaller et. al. Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001. Journal of Clinical Microbiology 41(4), 1440-1446.

2003. Y.C. Chen et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. Journal of Clinical Microbiology 52, 71-77.

2001. L. Leibowitz et. al. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagnostic Microbiology and Infectious Disease 04, 27-33.

2000. J. Meis et. al. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagnostic Microbiology and Infectious Disease 36, 215-223.

1998. J. Bille. BIOMIC Vision Reading of Fluconazole Agar Disk Diffusion Susceptibility Testing of Candida Spp. Clinical Isolates Compared to CLSI Microbroth Dilution. Poster J-120, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

1997. J. Bille, M. Glauser et. al: Evaluation of the Susceptibility of Pathogenic Candida Species to Fluconazole. European Journal of Clinical Microbiology and Infectious Disease 16(12), 924-928.

1997. J. Rex, M. Pfaller, J. Galgiani, M. Bartlett, A. Espinel-Ingroff, M. Ghannoum, M. Lancaster, F. Odds, M. Rinaldi, T. Walsh and A. Barry. Development of Interpretive Breakpoints for Antifungal Susceptibility Testing; Conceptual Framework and Analysis of In Vitro and In Vivo Correlation data for Fluconazole and Itraconazole and Candida Infections. Clinical Infectious Diseases 24, 235-247.

1996. A. Barry and S. Brown. Fluconazole Disk Diffusion Procedure for Determining Susceptibility of Candida Species. Journal of Clinical Microbiology 34, 2154-2157.